Did you know the global GLP-1 market, featuring drugs like Ozempic, could surpass $100 billion by 2030? Originally developed to treat diabetes, these therapies are now reshaping weight management and redefining biotechnology. In this episode of Tech4Sight, Diana Daniels hosts Glen Travers, a biotech pioneer, to discuss the innovations revolutionizing global health. Here’s what you’ll learn: • 🚀 How GLP-1 therapies are transforming obesity and diabetes care. • 🧬 The connection between biotechnology and lifestyle changes. • 💡 The biggest challenges facing the biotech industry—and how to overcome them. • 🔮 Bold predictions for metabolic health and the future of healthcare. Glen shares unique insights from decades of experience at the intersection of science, investment, and technology. This episode is a must-listen for leaders and innovators eager to explore the future of health.